Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exicure, Inc. (Nasdaq: XCUR) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors a structured view of how this clinical-stage biotechnology company reports on its hematology-focused business. Exicure’s filings describe its evolution from an early-stage nucleic acid therapy developer to a company centered on burixafor (GPC-100), a small molecule CXCR4 antagonist being developed for stem cell mobilization and as a potential chemosensitizing agent in acute myeloid leukemia (AML).
Through periodic reports and current reports on Form 8-K, Exicure provides details on clinical and operational milestones, such as financial results for each quarter, going concern assessments, and significant corporate events. For example, 8-K filings reference press releases announcing quarterly cash positions, research and development and general and administrative expenses, and management’s view that substantial additional financing is needed to fund operations and strategic alternatives.
Proxy materials on Schedule 14A (DEF 14A) outline the company’s governance structure, annual meeting agenda, director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also describe virtual-only annual meeting logistics and voting procedures for Exicure stockholders.
Registration statements such as the Form S-1 filed by Exicure provide further context on its status as a smaller reporting company, the listing of its common stock on The Nasdaq Capital Market under the symbol XCUR, and the potential resale of shares by selling stockholders. Additional 8-K filings address topics like changes to the board of directors, internal financing arrangements, and Nasdaq listing compliance matters.
On Stock Titan, investors can access these SEC documents alongside AI-powered summaries that highlight key points in lengthy filings, such as risk disclosures, capital needs, and updates on the burixafor development program. Real-time integration with EDGAR helps surface new 10-Q, 10-K, 8-K, proxy, and registration filings as they become available, while insider transaction reports on Form 4 and other ownership-related filings can be reviewed to understand equity activity by directors and officers.
Exicure, Inc. Chief Accounting Officer Josh Miller reported a small tax-related share disposition. On February 16, 2026, 8 shares of common stock at $4.08 per share were withheld by Exicure to cover his tax obligation upon vesting of restricted stock units. After this withholding, Miller directly holds 301 shares of Exicure common stock. This was a tax-withholding disposition under code F, not an open-market sale.
Exicure, Inc. reported a leadership change, appointing Jung Soo Kim as Chief Executive Officer and President and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. These appointments follow the resignations of former CEO and President Andy Yoo and former CFO and Secretary Seung Ik Baik, effective February 9, 2026.
The company highlights Mr. Kim’s more than 20 years of experience in corporate strategy, capital markets and restructuring, and Mr. Lee’s background in governance restructuring, financial planning and regulatory compliance, including their current roles at AGEDB Technology. Exicure’s board also approved that CEO and Interim CFO services will be provided under executive services agreements with Innocircle Advisors Inc.
Exicure, Inc. reported significant leadership and board changes. On February 6, 2026, three directors — Andy Yoo, Seung Ik Baik, and Aejin Hwang — resigned from the Board effective February 9, 2026, with the company stating there were no disagreements over operations or policies.
The Board simultaneously appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with staggered terms through the 2026, 2027, and 2028 annual meetings, and named Mr. Cheon to the audit committee. Each new director will receive a
The Board also approved a one-time
Exicure, Inc. reported achieving the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., tied to completing a Phase 2 clinical trial of its novel stem cell mobilizer (CXCR4 inhibitor Burixafor, GPC‑100). The milestone was reached when the Clinical Study Report was formally submitted to the U.S. Food and Drug Administration on January 16, 2026. Under the agreement, Exicure must pay $1,000,000 to GPCR Therapeutics within 30 days, and completion of this milestone also triggers a future sublicensing income‑sharing ratio that increases Exicure’s participation in the long‑term economics of the program.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has updated its ownership report after selling part of its stake. On January 21, 2026, Exicure HiTron completed a share transfer of 258,367 common shares at $4.50 per share, for total proceeds of $1,162,651.5. The shares were sold under share transfer agreements dated December 30, 2025 and were transferred to Jeon Sungchan for liquidity purposes.
After this transaction, Exicure HiTron reports beneficial ownership of 1,598,947 Exicure common shares, which represents about 25.1% of the company’s outstanding common stock. The ownership percentages are based on 6,373,869 shares outstanding as of November 3, 2025, as disclosed in Exicure’s Form 10-Q.
Exicure HiTron Inc., a more than 10% owner of Exicure, Inc. (XCUR), reported a sale of common stock. On 01/21/2026, the reporting person sold 258,367 shares of Exicure common stock at a price of $4.5 per share in an open-market transaction coded as "S" for sale.
After this transaction, Exicure HiTron Inc. beneficially owned 1,598,947 shares of Exicure common stock, held in direct ownership form. This filing is a routine Form 4 disclosure of insider activity and does not by itself describe any change to Exicure’s underlying business operations.
Exicure HiTron Inc. filed Amendment No. 4 to its Schedule 13D on Exicure, Inc., updating its ownership after a significant share transfer. On January 16, 2026, Exicure HiTron completed the transfer of 734,747 shares of Exicure common stock at $4.50 per share, for total proceeds of $3,306,361.5. The shares were transferred to Daolam Co., Ltd (246,913 shares), Lee So Jung (243,918 shares), and Kim Jun Sue (243,916 shares).
After these transfers, Exicure HiTron reports beneficial ownership of 1,857,314 shares of Exicure common stock, representing approximately 29.2% of the 6,373,869 shares outstanding as reported in Exicure’s Form 10-Q. The filing reflects updated ownership and transaction details but does not change Exicure HiTron’s status as a major shareholder.
Exicure HiTron Inc., a 10% owner of Exicure, Inc. (XCUR), reported an open market sale of 734,747 shares of common stock on January 16, 2026 at a price of $4.5 per share. After this transaction, Exicure HiTron Inc. beneficially owned 1,857,314 shares of Exicure common stock, held in direct ownership form.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has amended its beneficial ownership report after selling part of its stake. On January 7, 2026, Exicure HiTron completed share transfer agreements covering 741,272 common shares at
After giving effect to these transfers, Exicure HiTron reports beneficial ownership of 2,592,061 Exicure common shares, representing about
Exicure HiTron Inc., a 10% owner of Exicure, Inc. (XCUR), reported a sale of common stock. On January 7, 2026, the entity sold 741,272 shares of Exicure common stock at a price of $4.50 per share, coded as an open-market or similar sale. After this transaction, Exicure HiTron Inc. beneficially owned 2,592,061 common shares, held directly.